CellaVision announces new reporting date for the 2010 January - March interim report

The Board of CellaVision AB (publ) has decided to publish the January - March
2010 Interim Report on Friday, April 23, 2010 instead of, as previously
communicated, Thursday, April 29, 2010. Early publication allows CellaVision to
better prepare for its planned listing on NASDAQ OMX, Small Cap.


For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail:yvonne.martensson@cellavision.com
<mailto:yvonne.martensson@cellavision.com>

Johan Wennerholm, CFO, CellaVision AB
Phone: 46 708 33 81 68. E-mail:johan.wennerholm@cellavision.com
<mailto:johan.wennerholm@cellavision.com>


About CellaVision
CellaVision AB develops, markets, and sells market leading image analysis based
systems for routine analysis of blood and other body fluids. The company has a
core competence in development of software and hardware for automatic image
analysis of cells and cell changes for applications in health and medical care.
The company develops and markets systems for automatic differentials of white
blood cells and red morphology, and software for education and quality assurance
of differentials. The company's associates have expertise in advanced imaging
analysis, artificial intelligence, and automated microscopy.

The company headquarters are in Lund, Sweden. The company also has subsidiaries
in the US, Canada and Japan. For more information, please
visitwww.cellavision.com <http://www.cellavision.com/>.

CellaVision's share is listed on First North Premier at the OMX Stockholm Stock
Exchange. The company's Certified Advisor is Remium AB.



[HUG#1405827]